Genetically engineered Newcastle disease virus for prostate cancer: A magic bullet or a misfit

Expert Review of Anticancer Therapy

Volumn 13, Issue 7, 2013, Pages 769-772

  Elankumaran, Subbiah ^a  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

Newcastle disease virus; oncolytic virotherapy; oncolytic virus; prostate cancer; prostate specific antigen retargeting

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER CELL CULTURE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; GENETIC ENGINEERING; HUMAN; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVERALL SURVIVAL; PARTICLE SIZE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; QUALITY OF LIFE; REPEAT PROCEDURE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; TREATMENT RESPONSE; TUMOR XENOGRAFT; VESICULAR STOMATITIS VIRUS; VIRUS PARTICLE; VIRUS STRAIN;

EID: 84880789472     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2013.811062     Document Type: Review

References (30)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA. Cancer J. Clin. 59(4), 225-249 (2009
2. Medicine IO. Initial national priorities for comparative effectiveness research. National Academies Press, Washington, DC, USA, 1-253 (2009
3. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. 23(32), 8253-8261 (2005
4. Kozlowski JM, Ellis WJ, Grayhack JT. Advanced prostatic carcinoma. Early versus late endocrine therapy. Urol. Clin. North Am. 18(1), 15-24 (1991
5. Sinkovics JG. Progressive development of viral therapy of human cancers; a personal narrative account. In: Viral Therapy of Human Cancers. Sinkovics JG, Horvath JC (Eds.). Marcel Dekker, New York, NY, USA, 1-148 (2005
6. Wheelock EF, Dingle JH. Observations on the repeated administration of viruses to a patient with acute leukemia: A preliminary report. N. Engl. J. Med. 271, 645-651 (1964
7. Cassel WA, Garrett RE. Newcastle disease virus as an antineoplastic agent. Cancer 18, 863-868 (1965
8. Zamarin D, Palese P. Oncolytic Newcastle disease virus for cancer therapy: Old challenges and new directions. Future Microbiol. 7(3), 347-367 (2012
9. Breitbach CJ, Burke J, Jonker D et al. Intravenous delivery of a multi-mechanistic cancer-Targeted oncolytic poxvirus in humans. Nature 477(7362), 99-102 (2011
10. Echchgadda I, Kota S, DeLa Cruz I et al. Anticancer oncolytic activity of respiratory syncytial virus. Cancer Gene Ther. 16(12), 923-935 (2009
11. Kawaguchi Y, Miyamoto Y, Inoue T, Kaneda Y. Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle. Int. J. Cancer 124(10), 2478-2487 (2009
12. Liu C, Hasegawa K, Russell SJ, Sadelain M, Peng KW. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. Prostate 69(10), 1128-1141 (2009
13. Carey BL, Ahmed M, Puckett S, Lyles DS. Early steps of the virus replication cycle are inhibited in prostate cancer cells resistant to oncolytic vesicular stomatitis virus. J. Virol. 82(24), 12104-12115 (2008
14. Krishnamurthy S, Huang Z, Samal SK. Recovery of a virulent strain of newcastle disease virus from cloned cDNA: Expression of a foreign gene results in growth retardation and attenuation. Virology 278(1), 168-182 (2000
15. Aghi M, Martuza RL. Oncolytic viral therapies -The clinical experience. Oncogene 24(52), 7802-7816 (2005
16. Phuangsab A, Lorence RM, Reichard KW, Peeples ME, Walter RJ. Newcastle disease virus therapy of human tumor xenografts: Antitumor effects of local or systemic administration. Cancer Lett. 172(1), 27-36 (2001
17. Elankumaran S, Rockemann D, Samal SK. Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic dependent pathways of cell death. J. Virol. 80(15), 7522-7534 (2006
18. Biswas M, Kumar SR, Allen A et al. Celltype-specific innate immune response to oncolytic Newcastle disease virus. Viral Immunol. 25(4), 268-276 (2012
19. Elankumaran S, Chavan V, Qiao D et al. Type I interferon-sensitive recombinant Newcastle disease virus for oncolytic virotherapy. J. Virol. 84(8), 3835-3844 (2010
20. Biswas M, Johnson JB, Kumar SR, Parks GD, Elankumaran S. Incorporation of host complement regulatory proteins into Newcastle disease virus enhances complement evasion. J. Virol. 86(23), 12708-12716 (2012
21. Shobana R, Samal SK, Elankumaran S. Prostate-specific antigen-retargeted recombinant Newcastle disease virus for prostate cancer virotherapy. J. Virol. 87(7), 3792-3800 (2013
22. Rajput R, Sehgal A. Endocrine manipulations in cancer prostate: A review. Indian J. Endocrinol. Metab. 16(Suppl. 2), S199-S204 (2012
23. Palmberg C, Koivisto P, Visakorpi T, Tammela TL. PSA decline is an independent prognostic marker in hormonally treated prostate cancer. Eur. Urol. 36(3), 191-196 (1999
24. Oh WK, Halabi S, Kelly WK et al.; Cancer and Leukemia Group B 99813. A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colonystimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer 98(12), 2592-2598 (2003
25. Cooperberg MR. Thwarting high-risk prostate cancer: The right treatments for the right patients. Eur. Urol. 61(6), 1107-1109 (2012
26. Warde P, Mason M, Ding K et al.; NCIC CTG PR.3/MRC UK PR07 investigators. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: A randomised, Phase 3 trial. Lancet 378(9809), 2104-2111 (2011
27. Bourke L, Kirkbride P, Hooper R, Rosario AJ, Chico TJ, Rosario DJ. Endocrine therapy in prostate cancer: Time for reappraisal of risks, benefits and cost-effectiveness? Br. J. Cancer 108(1), 9-13 (2013
28. Keating NL, OMalley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: Observational study of veterans with prostate cancer. J. Natl Cancer Inst. 102(1), 39-46 (2010
29. Thompson CB, Shepard HM, OConnor PM et al. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol. Cancer Ther. 9(11), 3052-3064 (2010
30. Song KY, Wong J, Gonzalez L, Sheng G, Zamarin D, Fong Y. Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer. J. Mol. Med. 88(6), 589-596 (2010